107 related articles for article (PubMed ID: 26637909)
1. Treosulfan in the Treatment of Advanced Ovarian Cancer - Results of a German Multicenter Non-interventional Study.
Chekerov R; Kaltenecker G; Reichert D; Göhler T; Klare P; Oskay-Özcelik G; Sauer U; Wischnik A; Vehling-Kaiser U; Becker M; Hutzschenreuter U; Ammon A; Heidrich-Lorsbach E; Sehouli J
Anticancer Res; 2015 Dec; 35(12):6869-75. PubMed ID: 26637909
[TBL] [Abstract][Full Text] [Related]
2. A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO).
Sehouli J; Tomè O; Dimitrova D; Camara O; Runnebaum IB; Tessen HW; Rautenberg B; Chekerov R; Muallem MZ; Lux MP; Trarbach T; Gitsch G
J Cancer Res Clin Oncol; 2017 Mar; 143(3):541-550. PubMed ID: 27896440
[TBL] [Abstract][Full Text] [Related]
3. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
[TBL] [Abstract][Full Text] [Related]
4. Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: feasibility and toxicity.
Meden H; Wittkop Y; Kuhn W
Anticancer Res; 1997; 17(3C):2221-3. PubMed ID: 9216692
[TBL] [Abstract][Full Text] [Related]
5. A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis.
Mahner S; Oskay-Özcelik G; Heidrich-Lorsbach E; Fuxius S; Sommer H; Klare P; Belau A; Ruhmland B; Heuser T; Kölbl H; Markmann S; Sehouli J
J Cancer Res Clin Oncol; 2012 Aug; 138(8):1413-9. PubMed ID: 22526159
[TBL] [Abstract][Full Text] [Related]
6. Treosulfan in platinum-resistant ovarian cancer.
Olesen KD; Larsen ATR; Jensen LH; Steffensen KD; Søndergaard SR
Int J Gynecol Cancer; 2021 Jul; 31(7):1045-1051. PubMed ID: 34006568
[TBL] [Abstract][Full Text] [Related]
7. Treosulfan as an effective second-line therapy in ovarian cancer.
Gropp M; Meier W; Hepp H
Gynecol Oncol; 1998 Oct; 71(1):94-8. PubMed ID: 9784326
[TBL] [Abstract][Full Text] [Related]
8. Treosulfan in the treatment of metastatic renal cell carcinoma.
Rigos D; Wechsel HW; Bichler KH
Anticancer Res; 1999; 19(2C):1549-52. PubMed ID: 10365143
[TBL] [Abstract][Full Text] [Related]
9. Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer.
Hilger RA; Jacek G; Oberhoff C; Kredtke S; Baumgart J; Seeber S; Scheulen ME
Cancer Chemother Pharmacol; 2000; 45(6):483-8. PubMed ID: 10854136
[TBL] [Abstract][Full Text] [Related]
10. Treosulfan in the treatment of advanced ovarian cancer: a randomised co-operative multicentre phase III-study.
Breitbach GP; Meden H; Schmid H; Kühn W; Sass G; Schach S; Schmidt-Rohde P; Bastert G;
Anticancer Res; 2002; 22(5):2923-32. PubMed ID: 12530019
[TBL] [Abstract][Full Text] [Related]
11. Treosulfan in the treatment of metastatic melanoma: from chemosensitivity testing to clinical trials.
Neuber K
Recent Results Cancer Res; 2003; 161():159-79. PubMed ID: 12528807
[TBL] [Abstract][Full Text] [Related]
12. Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma.
Masding J; Sarkar TK; White WF; Barley VL; Chawla SL; Boesen E; Rostom AY; Menday AP
Br J Obstet Gynaecol; 1990 Apr; 97(4):342-51. PubMed ID: 2187525
[TBL] [Abstract][Full Text] [Related]
13. Treatment of active secondary progressive multiple sclerosis with treosulfan.
Wiendl H; Kieseier BC; Weissert R; Mylius HA; Pichlmeier U; Hartung HP; Melms A; Kuker W; Weller M
J Neurol; 2007 Jul; 254(7):884-9. PubMed ID: 17446994
[TBL] [Abstract][Full Text] [Related]
14. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study.
Spieth K; Kaufmann R; Gille J
Cancer Chemother Pharmacol; 2003 Nov; 52(5):377-82. PubMed ID: 12879280
[TBL] [Abstract][Full Text] [Related]
15. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies.
Scheulen ME; Hilger RA; Oberhoff C; Casper J; Freund M; Josten KM; Bornhäuser M; Ehninger G; Berdel WE; Baumgart J; Harstrick A; Bojko P; Wolf HH; Schindler AE; Seeber S
Clin Cancer Res; 2000 Nov; 6(11):4209-16. PubMed ID: 11106234
[TBL] [Abstract][Full Text] [Related]
16. Oral treosulfan as second-line treatment in platinum-resistant ovarian cancer: a phase II study. The Danish Ovarian Cancer Study Group.
Keldsen N; Madsen EL; Havsteen H; Kamby C; Laursen L; Sandberg E
Gynecol Oncol; 1998 May; 69(2):100-2. PubMed ID: 9625618
[TBL] [Abstract][Full Text] [Related]
17. Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation.
Bojko P; Hilger RA; Ruehm SG; Dirsch O; Seeber S; Scheulen ME
Bone Marrow Transplant; 2003 Mar; 31(6):487-91. PubMed ID: 12665845
[TBL] [Abstract][Full Text] [Related]
18. A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG).
Reed NS; Poole CJ; Coleman R; Parkin D; Graham JD; Kaye SB; Ostrowski J; Duncan I; Paul J; Hay A;
Eur J Cancer; 2006 Jan; 42(2):179-85. PubMed ID: 16337372
[TBL] [Abstract][Full Text] [Related]
19. Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial.
Neuber K; Reinhold U; Deutschmann A; Pföhler C; Mohr P; Pichlmeier U; Baumgart J; Hauschild A
Melanoma Res; 2003 Feb; 13(1):81-5. PubMed ID: 12569289
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer.
du BA; Meier W; Lück HJ; Emon G; Moebus V; Schroeder W; Costa S; Bauknecht T; Olbricht S; Jackisch C; Richter B; Wagner U
Ann Oncol; 2002 Feb; 13(2):251-7. PubMed ID: 11886002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
